ClinConnect ClinConnect Logo
Search / Trial NCT06082518

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Oct 12, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Hyperbaric Oxygen Therapy Hbot Post Covid 19 Condition Fatigue Severe Acute Respiratory Syndrome Co V 2 Covid 19

ClinConnect Summary

This clinical trial is looking at a new treatment for people who still feel unwell after recovering from COVID-19, a condition often called post COVID-19 syndrome. Many individuals experience ongoing symptoms like chronic fatigue, which is a constant feeling of tiredness and low energy. The trial will test a treatment called hyperbaric oxygen therapy, where patients spend time in a special chamber that delivers high levels of oxygen. This therapy may help reduce fatigue and improve overall well-being.

To participate in the trial, you must be at least 18 years old, have been officially diagnosed with post COVID-19 syndrome by a doctor, and have been experiencing symptoms for more than 12 weeks after your COVID-19 infection. Patients who have certain health issues, such as severe heart problems or other serious medical conditions, may not be eligible. If you join the study, you can expect to receive the hyperbaric oxygen therapy and help researchers understand if this treatment is effective for alleviating symptoms of post COVID-19 syndrome. The findings could lead to larger studies in the future, helping many people who are struggling with ongoing health issues after COVID-19.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years old
  • 2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner
  • 3. At least three months since SARS-CoV-2 infection
  • 4. Symptoms that persist more than 12 weeks:
  • * Chronic fatigue (must include) along with one of the following symptoms:
  • Difficulty thinking or problem solving ('brain fog')
  • Stress or anxiety
  • Exclusion Criteria:
  • 1. Contraindications/medically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)
  • 2. Patients with cognitive difficulties and/or mental retardation before COVID diagnosis
  • 3. History of traumatic brain injury
  • 4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)
  • 5. Known pregnancy or planning a pregnancy in women of childbearing age

About Sunnybrook Health Sciences Centre

Sunnybrook Health Sciences Centre is a leading academic health science organization located in Toronto, Canada, renowned for its commitment to advancing patient care through innovative research and education. As a prominent clinical trial sponsor, Sunnybrook integrates cutting-edge medical research with clinical practice, focusing on a wide range of health disciplines, including cancer care, trauma, and cardiovascular health. The center collaborates with various stakeholders, including academic institutions, healthcare providers, and industry partners, to facilitate the development of novel therapies and improve health outcomes. With a robust infrastructure and a dedicated team of researchers and clinicians, Sunnybrook plays a pivotal role in translating scientific advancements into tangible benefits for patients.

Locations

Toronto, Ontario, Canada

Patients applied

CP

1 patients applied

Trial Officials

Fahad Alam, MD

Principal Investigator

Sunnybrook Health Sciences Centre

Jordan Tarshis, MD

Principal Investigator

Sunnybrook Health Sciences Centre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported